ImmunityBio: Funding, Investors & Team (Oct 2026)
The goal of ImmunityBio, Inc. (previously NantKwest, Inc.) is to create cell and immunotherapy treatments that will help patients' natural immune systems get stronger so that they can potentially combat illness and get rid of malignant or infected cells. The innate immune system's activation is essential for the formation of immunological memory. Our founder and executive chairman, Dr. Patrick Soon-Shiong, has been researching ways to get the immune system going in order to fight malignancies that would otherwise be able to elude and outsmart the body's defences for the past 20 years. Abraxane, the first protein nanoparticle medication ever created, was the inspiration for the following wave of immunotherapies, which were the focus of Dr. Soon-research. Shiong's In order to solve the severe unmet requirements in oncology and infectious illnesses, ImmunityBio was established in 2014.
ImmunityBio has raised $60.7M across 2 funding rounds on record, the most recent an undisclosed round of $50.0M announced in Feb 2023.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
ImmunityBio Company Profile and Key Stats
Latest funding round on record: Feb 2023.
ImmunityBio Funding Rounds
ImmunityBio raised $10.7M in a Post-IPO Equity announced in Jul 2022.
7 months later, an undisclosed round of $50.0M was announced in Feb 2023.
ImmunityBio Founders and Leadership Team
Contact details for the ImmunityBio team: 1 of 1 has an email address on file.
Start 14-day free trial →ImmunityBio Funding Compared to Other Health Care Startups
ImmunityBio's latest round of $50.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImmunityBio in Health Care and Culver City
Companies Similar to ImmunityBio
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
ImmunityBio Funding FAQs
What does ImmunityBio do?
The goal of ImmunityBio, Inc. (previously NantKwest, Inc.) is to create cell and immunotherapy treatments that will help patients' natural immune systems get stronger so that they can potentially combat illness and get rid of malignant or infected cells. The innate immune system's activation is essential for the formation of immunological memory. Our founder and executive chairman, Dr. Patrick Soon-Shiong, has been researching ways to get the immune system going in order to fight malignancies that would otherwise be able to elude and outsmart the body's defences for the past 20 years. Abraxane, the first protein nanoparticle medication ever created, was the inspiration for the following wave of immunotherapies, which were the focus of Dr. Soon-research. Shiong's In order to solve the severe unmet requirements in oncology and infectious illnesses, ImmunityBio was established in 2014.
How much funding has ImmunityBio raised?
ImmunityBio has raised $60.7M across 2 rounds on record. The most recent is an undisclosed round of $50.0M announced in Feb 2023.
When did ImmunityBio last raise funding?
ImmunityBio's most recent funding round on record is an undisclosed round of $50.0M, announced in Feb 2023.
Who is the CEO of ImmunityBio?
Richard Adcock is listed as CEO at ImmunityBio.
Where is ImmunityBio headquartered?
ImmunityBio is based in Culver City, California, United States.
How many employees does ImmunityBio have?
ImmunityBio is in the 101-250 employee band.
How does ImmunityBio's funding compare to other Health Care startups?
ImmunityBio's latest round of $50.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's ImmunityBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImmunityBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.